文献速递肿瘤 PET/CT

非小细胞肺癌中PD-L1表达与FDG PET/CT代谢参数及临床病理特征的相关性

PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.
PubMed 文献 · EJNMMI Res · 2020-05-19

本研究纳入374例非小细胞肺癌患者,比较FDG PET/CT代谢参数(SUVmax、MTV-P、TLG-P、MTV-C、TLG-C)与PD-L1阳性表达及临床病理特征的关系。PD-L1阳性率为27.8%(104/374),SUVmax、TLG-P、TLG-C在PD-L1阳性组显著高于阴性组;多因素分析显示仅SUVmax是PD-L1阳性的独立预测因子。以SUVmax cut-off值12.5预测PD-L1状态,灵敏度65.4%、特异度86.7%、准确率80.7%。

要点

  • PD-L1阳性率为27.8%(104/374),腺癌21.6%(61/283)、鳞癌47.5%(43/91)。
  • SUVmax、TLG-P、TLG-C在PD-L1阳性组显著高于阴性组。
  • 仅SUVmax是整体NSCLC、腺癌和鳞癌中PD-L1阳性的独立预测因子。

核心结论

  • NSCLC的PD-L1表达与SUVmax、TLG、男性、吸烟和中央型位置相关。
  • 仅SUVmax是PD-L1阳性的独立预测因子,可帮助探究免疫检查点的存在。

研究设计与样本

  • 回顾性分析374例NSCLC患者(男215例、女159例,年龄63±9岁),包括283例腺癌和91例鳞癌。
  • 比较FDG PET/CT代谢参数(SUVmax、MTV-P、TLG-P、MTV-C、TLG-C)与PD-L1阳性表达及临床病理特征。

主要发现

  • PD-L1阳性率为27.8%(104/374);腺癌为21.6%(61/283),鳞癌为47.5%(43/91)。
  • SUVmax、TLG-P、TLG-C在PD-L1阳性组显著高于PD-L1阴性组。
  • PD-L1表达与男性、吸烟和中央型NSCLC明显相关。
  • 分别分析腺癌和鳞癌时,仅SUVmax与PD-L1表达明显相关。
  • 多因素分析显示,在整体NSCLC、腺癌和鳞癌中仅SUVmax是PD-L1阳性表达的独立预测因子。

关键数值与推荐

  • 以SUVmax cut-off值12.5预测NSCLC的PD-L1状态,灵敏度65.4%、特异度86.7%、准确率80.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring PD-L1 expression could help to select NSCLC candidates for immunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) PET/CT could provide phenotypic information on malignant tumors. Thus, this study investigated PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in NSCLC. METHODS: FDG PET/CT metabolic parameters including maximum standard uptake (SUVmax), metabolic tumor volume and total lesion glycolysis of primary lesion (MTV-P, TLG-P), and combination of primary lesion and metastases (MTV-C, TLG-C) were compared with PD-L1-positive expression in patients with NSCLC. Moreover, clinicopathological characteristics, including age, gender, smoking history, serum tumor markers, tumor location, size, TNM stage, and genetic mutation were also reviewed. RESULTS: All 374 patients (215 men; 159 women; age 63 ± 9 years) included 283 adenocarcinomas (ACs) and 91 squamous cell carcinomas (SCCs). PD-L1 expression was positive in 27.8% (104/374) cases. SUVmax, TLG-P, and TLG-C of PD-L1 positivity were significantly higher than PD-L1 negativity. Moreover, PD-L1 expression was obviously correlated with man, smoking, and central NSCLC. If ACs and SCCs were separately analyzed, PD-L1 positivity in ACs and SCCs was 21.6% (61/283) and 47.5% (43/91), respectively, and only SUVmax was obviously associated with PD-L1 expression. Furthermore, multivariate analysis revealed that only SUVmax was an independent predictor of PD-L1 positive expression in overall NSCLC, AC, and SCC. Using a SUVmax cut-off value of 12.5, PD-L1 status of NSCLC was predicted by FDG PET/CT with sensitivity, specificity, and accuracy of 65.4%, 86.7%, and 80.7%, respectively. CONCLUSIONS: PD-L1 expression of NSCLC was related to SUVmax, TLG, man, smoking, and central location. However, only SUVmax was an independent predictor of PD-L1 positivity, which could help to explore the existence of immune checkpoints.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Wu X, Huang Y, Zhao Q, et al. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer. EJNMMI Res. 2020. PMID: 32430866. doi:10.1186/s13550-020-00639-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。